Active Products definition

Active Products means Products listed on TFM’s then current month’s order guide.
View Source
Active Products means (i) the Products Dexpak 6 Day, Dexpak 10 Day, Dexpak 13 Day, ▇▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇ ▇▇▇▇▇, (▇▇) any product that is sold, marketed or distributed by Purchaser following the Closing Date using a trade or brand name listed in clause (i), (iii) any product that is sold, marketed or distributed by Purchaser following the Closing Date using the existing formulation of a Product listed in clause (i) or a formulation having the same active ingredients, dosage form and release rate as a Product listed in clause (i)and (iv) any product that is sold, marketed or distributed by Purchaser following the Closing Date using the same active ingredients, dosage form and release rate as an Inactive Product.
View Source

Examples of Active Products in a sentence

  • Without limitation of the generality of the foregoing, the Parties shall use Commercially Reasonable Efforts to complete the transition of the Manufacture, Development and Commercialization of any Active Products hereunder to Manufacture, Development, Commercialization of such Active Products by Genentech and Tanox or their respective designees as soon as is reasonably possible.

  • Such technology transfer agreement shall include a license from Novartis to Manufacture such Active Product under Anti-IgE Patents, Company Information, and Know-How Controlled by Novartis and existing at the effective date of termination which are reasonably required, or to the extent they are used as at the effective date of termination, to Manufacture Active Products.

  • Except as shown on Schedule 8.5 attached hereto, the Inventory of each Active Product shall equal or exceed a two-month supply based upon Seller’s average monthly sales of such Active Products for the last three calendar years.

  • Without limitation of the generality of the foregoing, the Parties shall use commercially reasonable efforts to complete the transition of the Manufacture, Development and Commercialization of any Active Products hereunder to Manufacture, Development, Commercialization of such Active Products solely by Tanox or its designees as soon as is reasonably possible.

  • Genentech shall transfer and assign to Novartis (or its nominee) all Approvals and regulatory filings made or obtained by Genentech or its Affiliates or any of its sublicensees with respect to the Active Products (other than Approvals for manufacturing facilities).

  • The Terminating Party(ies) shall transfer and assign to Tanox (or its nominee) all Approvals and regulatory filings made or obtained by the Terminating Party(ies) or its Affiliates or any of its sublicensees with respect to the Active Products (other than Approvals for manufacturing facilities).

  • In the event any regulatory action prohibits the sale or shipment of the Active Products Lodrane 24, Lodrane 24D or Lodrane 12D subject to any grace or other period during which Purchaser and its Affiliates can continue to sell or ship such Active Products, the payment obligations herein shall continue in full force during such grace or other period and the sales of such Active Products shall be included in Net Sales in calculating any payments due hereunder.

  • Without limitation of the generality of the foregoing, the Parties shall use Commercially Reasonable Efforts to complete the transition of the Manufacture, Development and Commercialization of any Active Products hereunder to Manufacture, Development, Commercialization of such Active Products solely by Novartis or its designees as soon as is reasonably possible.

  • Such technology transfer agreement shall include a license from Genentech to Manufacture such Active Product under Anti-IgE Patents, Company Information, and Know-How Controlled by Genentech and existing at the effective date of termination which are reasonably required, or to the extent they are used as at the effective date of termination, to Manufacture Active Products.

  • No such quarterly payments shall be due and payable until Purchaser and its Affiliates have Net Sales of Active Products for the applicable 12 month period exceed $10,000,000, at which time the payments with respect to any preceding quarter(s) shall be included in the payment made with respect to the quarter in which such threshold was exceeded.